These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 14511294

  • 1. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
    Steen Carlsson K, Höjgård S, Glomstein A, Lethagen S, Schulman S, Tengborn L, Lindgren A, Berntorp E, Lindgren B.
    Haemophilia; 2003 Sep; 9(5):555-66. PubMed ID: 14511294
    [Abstract] [Full Text] [Related]

  • 2. Prophylaxis for severe haemophilia: clinical and economical issues.
    Fischer K, Van Den Berg M.
    Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
    [Abstract] [Full Text] [Related]

  • 3. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
    Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, De Kleijn P, Grobbee DE, van den Berg HM.
    Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642
    [Abstract] [Full Text] [Related]

  • 4. The overall effectiveness of prophylaxis in severe haemophilia.
    Panicker J, Warrier I, Thomas R, Lusher JM.
    Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
    [Abstract] [Full Text] [Related]

  • 5. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD, Association of Hemophilia Clinic Directors of Canada (AHCDC), Canadian Association of Nurses in Hemophilia Care (CANHC).
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [Abstract] [Full Text] [Related]

  • 6. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R, Gretenkort Andersson N.
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
    Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, van den Berg HM.
    Haemophilia; 2002 Nov; 8(6):753-60. PubMed ID: 12410643
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K, Walker I, Decker K, Chan AK, Pai MK.
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [Abstract] [Full Text] [Related]

  • 13. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C, Watts RG.
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [Abstract] [Full Text] [Related]

  • 14. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D, Ono F, De Oliveira GB, Almeida J, De Paula JC, Batista Neto LV, Silva Barros SB.
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [Abstract] [Full Text] [Related]

  • 15. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.
    Osooli M, Steen Carlsson K, Astermark J, Berntorp E.
    Haemophilia; 2017 Sep; 23(5):e403-e408. PubMed ID: 28758324
    [Abstract] [Full Text] [Related]

  • 16. Update on treatment regimens: prophylaxis versus on-demand therapy.
    Manco-Johnson MJ.
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
    [Abstract] [Full Text] [Related]

  • 17. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
    Fischer K, Lewandowski D, Janssen MP.
    Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
    [Abstract] [Full Text] [Related]

  • 18. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B, Lian X, Li K, Lee A, Poon MC, Zhao Y.
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [Abstract] [Full Text] [Related]

  • 19. Aspects of haemophilia prophylaxis in Sweden.
    Ljung RC.
    Haemophilia; 2002 Mar; 8 Suppl 2():34-7. PubMed ID: 11966851
    [Abstract] [Full Text] [Related]

  • 20. Primary prophylaxis in children with haemophilia.
    Coppola A, Di Capua M, De Simone C.
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s4-11. PubMed ID: 19105503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.